Exchange: NASDAQ·Updated 04:20 PM EST

CSTL News

News
all
press releases
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First CulturePR NewswireFRIENDSWOOD, Texas, Nov. 12, 2026 Regional honors in Houston, Arizona and Pittsburgh, national healthcare...
PR Newswire
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First CulturePR NewswireFRIENDSWOOD, Texas, Nov. 12, 2026 Regional honors in Houston, Arizona and Pittsburgh, national healthcare...
PR Newswire
More News
Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare ConferencePR NewswireFRIENDSWOOD, Texas, Nov. 11, 2026 FRIENDSWOOD, Texas, Nov. 11, 2026 /PRNewswire/ -- Castle Biosciences, Inc.(Nasdaq...
PR Newswire
DecisionDx-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging DecisionDx-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC StagingPR NewswireFRIENDSWOOD, Texas, Nov. 11, 2026...
PR Newswire
The consensus price target hints at a 37% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Castle Biosciences (CSTL) delivered earnings and revenue surprises of +65.79% and +11.84%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Castle Biosciences Reports Third Quarter 2026 Results Castle Biosciences Reports Third Quarter 2026 ResultsPR NewswireFRIENDSWOOD, Texas, Nov. 5, 2026 Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025TissueCypher test report volume increased 47% over Q3 2025Raising...
PR Newswire
Castle Biosciences to Participate in Upcoming Investor Conferences Castle Biosciences to Participate in Upcoming Investor ConferencesPR NewswireFRIENDSWOOD, Texas, Oct. 28, 2026 FRIENDSWOOD, Texas, Oct. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc.(Nasdaq: CSTL), a company improving health...
PR Newswire
Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026 Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026PR NewswireFRIENDSWOOD, Texas, Oct. 15, 2026FRIENDSWOOD, Texas, Oct. 15, 2026...
PR Newswire
ACG 2026 Data Show TissueCypher Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus ACG 2026 Data Show TissueCypher Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's EsophagusPR NewswireFRIENDSWOOD, Texas, Oct. 12, 2026Studies...
PR Newswire
Late-Breaking EADV 2026 Data Support Use of DecisionDx-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management Late-Breaking EADV 2026 Data Support Use of DecisionDx-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical ManagementPR NewswireFRIENDSWOOD, Texas, Sept. 30...
PR Newswire

Advertisement|Remove ads.